66.7 F
New York
Monday, October 2, 2023



Vesalio Initiates Clinical Study Evaluating Innovative Thrombectomy Technique for Patients with STEMI

Related Articles

ThinkOrbital Hires Former SpaceX, Blue Origin Engineering Manager Brian Corr as Director of Integration and Testing

Boulder, CO, October 01, 2023 --(PR.com)-- ThinkOrbital, a leading U.S.-based space construction and infrastructure company, announced Brian Corr as its new Director of Integration and...

Space Research Incubator Addressing Methane Emissions Using Satellite Data Welcomes 20 Teams from Australia, New Zealand, Philippines, New Caledonia and East Timor

Auckland, New Zealand, September 26, 2023 --(PR.com)-- SpaceBase today announces the Space for Planet Earth Virtual Research Incubator Teams across the Pacific region. Teams include:High...
Nashville, TN, December 23, 2021 –(PR.com)– Today, Vesalio announced the start of enrollment in its NATURE study using enVast™, the company’s first thrombectomy system for patients presenting with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention.

NATURE is a randomized, multi-center clinical trial comparing the safety and efficacy of enVast™ as an adjunctive measure to conventional intervention versus the standard of care in STEMI patients with large thrombus burden.

The first patient in the study was enrolled by Professor Marco Valgimigli, Deputy Chief of Cardiology at Cardiocentro Ticino Istituto, in Lugano, Switzerland.

“Our first-in-human case series of 61 STEMI patients with large thrombus burden allowed us to develop a safe and effective thrombectomy technique using the enVast™ stent retriever under continuous aspiration. With the NATURE study, our goal is to…

Read more…

Popular Articles